Based on the data gathered, we propose, for the first time, that SOC therapies used in ER+ breast cancer reduce the expressions of DNA repair proteins, XRCC1, FEN1, BRCA1, BRCA2 and RAD51, caretakers in maintaining genomic integrity. This evidence concerns the gene XRCC1 and breast carcinoma.